In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Gilead Sciences, Inc.

http://www.gilead.com

Latest From Gilead Sciences, Inc.

How Significant Will Veklury’s Sales Be? Forecasts Show It Is Hard To Tell

Veklury is now the first US FDA-approved treatment for COVID-19, but its limited benefits means its lifespan as a blockbuster could be short.

Commercial Companies

Muted Q2 But Biocon Confident Of Insulin Glargine’s Onward US March

Biocon Biologics upbeat on Lantus follow-on’s long revenue stream and prospects for interchangeability, while operational challenges resulted in some supply constraints during the fiscal second quarter.

Commercial Sales & Earnings

Muted Q2 But Biocon Confident Of Insulin Glargine’s Onward US March

Biocon Biologics upbeat on Lantus follow-on’s long revenue stream and prospects for interchangeability, while operational challenges resulted in some supply constraints during the fiscal second quarter.

Commercial Biosimilars

Speedy Approval Of Gilead’s Veklury Sets Stage For Pediatric Expansion, Dosing Refinement

US FDA looks to post-marketing studies to address elements of the NDA that were not central to its initial swift approval as the first COVID-19 therapy, including pediatric use and the interaction of hepatotoxicity and dose duration.

Post Market Regulation & Studies Approvals
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
    • Drug Delivery
    • Specialty Pharmaceuticals
  • Other Names / Subsidiaries
    • Arresto Biosciences, Inc.
    • Asegua Therapeutics, LLC
    • Calistoga Pharmaceuticals, Inc.
    • CGI Pharmaceuticals, Inc.
    • CV Therapeutics, Inc.
    • Cytopia Limited
    • EpiTherapeutics
    • Eximias Pharmaceutical Corporation
    • Immunomedics, Inc.
    • Myogen
    • Nimbus Apollo, Inc.
    • Nexstar Pharmaceuticals
    • Oligogen, Inc.
    • Pharmasset, Inc.
    • Triangle Pharmaceuticals
    • YM BioSciences Inc. (YMI)
    • Kite Pharma, Inc.
    • Kite Pharma EU
    • T-Cell Factory B.V. (TCF)
    • Cell Design Labs, Inc.
    • Asegua Therapeutics
UsernamePublicRestriction

Register